Description

Contact hours available until 4/30/2022.

Requirements for Successful Completion:
Complete the learning activity in its entirety and complete the online CNE evaluation.

Nephrology Nursing Journal Editorial Board Statements of Disclosure:
In accordance with ANCC governing rules Nephrology Nursing Journal Editorial Board statements of disclosure are published with each CNE offering. The statements of disclosure for this offering are published below.

Paula Dutka, MSN, RN, CNN, disclosed that she is a coordinator of Clinical Trials for the following sponsors: Amgen, Rockwell Medical, Keryx Biopharmaceuticals, Akebia Therapeutics, and Dynavax Technologies.

Norma J. Gomez, MBA, MSN, CNNe, disclosed that she is a member of the ZS Pharma Advisory Council.

All other members of the Editorial Board had no actual or potential conflict of interest in relation to this continuing nursing education activity.

The authors reported no actual or potential conflict of interest.

This article was reviewed and formatted for contact hour credit by Beth Ulrich, EdD, RN, FACHE, FAONL, FAAN, Nephrology Nursing Journal Editor-in-Chief, and Sally Russell, MN, CMSRN, CPP, ANNA Education Director.

Accreditation Statement:
The American Nephrology Nurses Association (ANNA) is accredited with distinction as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation.

ANNA is a provider approved by the California Board of Registered Nursing, provider number CEP 00910.

This CNE article meets the Nephrology Nursing Certification Commission’s (NNCC’s) continuing nursing education requirements for certification and recertification.

Learning Outcome:
After completing this learning activity, the learner will be able to articulate the pharmacokinetics and pharmacodynamics of tolvaptan therapy in patients with autosomal dominant polycystic kidney disease (ADPKD); outline a plan of care for a patient with ADPKD, including assessment, diagnosis, health and lifestyle management, and tolvaptan therapy; and discuss initial and maintenance tolvaptan dosing, titration, and ongoing evaluation studies essential to safe tolvaptan therapy.

Author(s)

• Cheryl B. Hines, EdD, MSN, CRNA
• Gwendolyn L. Hooper, PhD, APRN-BC, FNP, CUNP
• Angela Collins-Yoder, PhD, RN, CCNS, ACNS, BC, SCRN